Latest Research And Development News

Island Pharmaceuticals has completed its acquisition of the broad-spectrum antiviral Galidesivir ahead of schedule, setting sights on expedited FDA approval leveraging the Animal Rule.

Knosys Limited sustains a robust $9.8 million Annual Recurring Revenue, extends its ANZ Bank contract, and accelerates AI-driven library technology development with promising early market feedback.

Percheron Therapeutics has licensed HMBD-002, a promising immuno-oncology candidate, completed FDA IND transfer, and plans to launch phase II trials in 2026. The company also reported a solid cash position and issued loyalty options to shareholders.

Dubber Corporation Limited has achieved underlying operating cashflow breakeven for the first time in its history in Q4 FY25, despite the looming impact of a major contract non-renewal. The company plans to offset margin losses through aggressive cost savings and revenue growth in FY26.

Zimi Limited has completed production of its Smoke Connect safety range, progressed Matter Connect certification, and moved Senoa manufacturing to a new facility, while engaging investors for a capital raise.

ReNerve Limited reported a robust 53% increase in annual revenue, driven by strategic partnerships and new regulatory approvals that broaden its global footprint in nerve repair.

BPH Global confirms that the seaweed Sesuvium portulacastrum accumulates valuable metals including gold and lithium, but shifts focus to biological extraction after chemical methods fall short.

Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.

Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.

ACDC Metals has reported strong scoping study results for its Goschen Central heavy mineral sands and rare earth project, highlighting a promising 14-year mine life and a strategic retention licence application to support ongoing development.

Neurizon Therapeutics has secured a $1.5 million loan against its expected 2025 R&D tax rebate, boosting liquidity without diluting shareholders. This strategic move supports ongoing development of its neurodegenerative disease treatments.

Green360 Technologies has made significant strides in low-carbon cement development through a joint venture with PERMAcast and reported strong financial growth at its Pittong kaolin operations. The company is progressing towards commercial-scale production of sustainable building materials while expanding into new markets.